Latest Articles in biogen
Alzheimer's Drug From Biogen, Eisai Slows Cognitive Decline, Side-effects In Focus
The drug, lecanemab, was associated with a dangerous type of brain swelling in nearly 13 per cent of patients in the trial that spanned 18 months and enrolled nearly 1,800 participants with early-stage Alzheimer's
Read More
USFDA Extends Review Of Biogen's ALS Drug
Biogen said it had submitted responses to the FDA's information requests, which the agency said would require additional time for review and set a new target action date of April 25, 2023
Read More
Eisai, Biogen Say Alzheimer's Drug Slows Cognitive Decline
Eisai and Biogen Inc on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs
Read More
US Pharma Biogen Lands $900 Mn Settlement With Its Whistleblower
As per the statement released by the US Justice Department on Monday, Michael Bawduniak, the whistleblower behind the report, will receive about $250 million directly. The rest will essentially go to the federal government
Read More
ALS Drug Shows Clinical Benefit Says Biogen
The Biogen drug, tofersen, is currently under priority review by the U.S. Food and Drug Administration with an approval decision expected by Jan 25
Read More